Overview

GnRH Agonist at Embryo Transfer: IVF Outcomes

Status:
Withdrawn
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
In ART (assisted reproductive technology) cycles, embryos are transferred to a woman's uterus after in-vitro fertilization (IVF) in a laboratory. Usually, hormones (progesterone) are given to the patient after transferring the embryo, as a supplement, in order to mimic the natural hormones that would normally be secreted in an unassisted pregnancy. This study will identify whether additional gonadotropin-releasing hormone (GnRH-agonist) administration, a natural hormone secreted from the hypothalamus, will improve the clinical pregnancy and live birth rates when using IVF.
Phase:
Phase 3
Details
Lead Sponsor:
Maimonides Medical Center
Treatments:
Deslorelin
Leuprolide
Pharmaceutical Solutions